“…Neuromodulation represents a growing frontier in modern medicine. In cancer pain, where epidemiologic studies approximate that 15% of patients fail to achieve acceptable pain levels through conventional pharmacologic management, the use of neurostimulation is being studied to see if stimulation can improve pain outcomes in comparison or addition to the implantation of intrathecal drug delivery pumps (ITP) (1). Yet, this patient cohort, from high‐risk pre‐diagnosis to posttreatment survivors, presents significant concerns for implanting physicians due to the increased likelihood of magnetic resonance (MR) scans post‐implantation.…”